JY
GNMX

Jeff Yass’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Jeff Yass’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-28,700
Closed -$35K – 10464
2018
Q3 		$35K Buy
+28,700
New +$32.1K ﹤0.01% 8917
2017
Q2 		– Sell
-32,000
Closed -$60K – 10158
2017
Q1 		$60K Sell
32,000
-344,600
-92% -$1.56M ﹤0.01% 8556
2016
Q4 		$1.95M Buy
+376,600
New +$1.98M ﹤0.01% 4117
2016
Q1 		– Sell
-23,500
Closed -$141K – 9992
2015
Q4 		$141K Buy
23,500
+1,900
+9% +$12.9K ﹤0.01% 8694
2015
Q3 		$169K Buy
21,600
+11,500
+114% +$89.1K ﹤0.01% 8833
2015
Q2 		$62K Buy
+10,100
New +$78.3K ﹤0.01% 9823
2014
Q4 		– Sell
-87,400
Closed -$454K – 10315
2014
Q3 		$454K Sell
87,400
-14,200
-14% -$91.6K ﹤0.01% 7389
2014
Q2 		$789K Buy
101,600
+18,400
+22% +$130K ﹤0.01% 6556
2014
Q1 		$581K Buy
83,200
+30,600
+58% +$239K ﹤0.01% 6497
2013
Q4 		$315K Buy
+52,600
New +$344K ﹤0.01% 7509

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $640M AUM 26.68% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Jeff Yass's GNMX Position: Q2 2019 in Review

Jeff Yass sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2019, closing a stake of 127,313 shares — an estimated $25K sold.

Jeff Yass first reported a position in GNMX in Q1 2014 and held it in 13 quarters. The position peaked at $412K in Q1 2015. 29 funds tracked by Wall St. Rank hold GNMX as of Q2 2019.

  • Jeff Yass reported no remaining Aevi Genomic Medicine Inc position as of Q2 2019 after selling out during the quarter.
  • Jeff Yass sold 127,313 Aevi Genomic Medicine Inc shares in Q2 2019, an estimated $25K.
  • Jeff Yass first reported a position in Aevi Genomic Medicine Inc in Q1 2014 and held it in 13 quarters.
  • Jeff Yass's Aevi Genomic Medicine Inc position peaked at $412K in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2019.

Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.